Applying the Allogeneic Process to Overcome Challenges in Cell Therapy

[On Demand]
Search General Info
Search Education
Search Partnering Companies
The commercial launch of approved cell therapies demonstrated to the industry and world alike, the transformative impact they can have on a patient’s life and the ability to revolutionize the treatment of human disease. As the industry is now turning to large-scale allogeneic therapies, which can impact a broader patient population, there is a focus on retaining more early memory T cells during ex vivo manufacturing. Examples of the advanced capabilities that will help us accomplish these goals include our state-of-the-art metabolic and proteomic understanding, robust T cell activation technologies and expansion media, and our deep understanding of how the workflow affects the cellular product. In this session, you will hear about the advantages of using allogeneic workflows and how to fine-tuning the manufacturing process can improve therapeutic performance.
Speaker
photo
Staff Scientist
Thermo Fisher Scientific